Trump Signs Executive Order to Accelerate Psychedelic Research and Funding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DFTX?
Source: stocktwits
- Policy Acceleration for Psychedelic Research: Trump signed an executive order directing federal agencies to expedite psychedelic research and approvals, committing $50 million for related clinical studies, which is expected to significantly shorten treatment drug approval timelines, thereby providing faster treatment options for mental health patients.
- Market Potential Analysis: Koyfin consensus estimates indicate that Compass Pathways (CMPS) has a 12-month average analyst price target of $21.75, implying a 227% upside, while Definium Therapeutics (DFTX) stands at $36.67, suggesting a 62% potential increase, highlighting CMPS's greater valuation upside following the policy shift.
- Clinical Trial Progress: Both Definium's DT120 (LSD-based) and Compass's COMP360 (psilocybin) are advancing through late-stage clinical trials in the U.S. targeting psychiatric conditions such as anxiety and depression, with the potential to offer new treatment options for patients, especially under Trump's supportive policy.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for both DFTX and CMPS is extremely bullish, with DFTX stock surging nearly 300% over the past year and CMPS more than doubling, reflecting strong market interest and confidence in psychedelic drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DFTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DFTX
Wall Street analysts forecast DFTX stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.460
Low
20.00
Averages
35.89
High
61.00
Current: 22.460
Low
20.00
Averages
35.89
High
61.00
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Definium Supports White House Executive Order on Mental Health
- Policy Support: Definium Therapeutics expresses support for the newly signed White House Executive Order aimed at accelerating research and development of innovative treatments for mental illness, highlighting the administration's recognition of unmet treatment needs in serious mental health conditions.
- Clinical Development Plan: The company is advancing a comprehensive clinical development program for DT120 (lysergide tartrate) targeting millions of patients with generalized anxiety disorder and major depressive disorder, aiming to provide new treatment options that enhance patient quality of life.
- FDA Approval Pathway: Definium emphasizes that the FDA's evidence-based approval process is the most effective route for safely translating new therapies into clinical use, ensuring patients have access to these innovative treatments.
- Technological Advantages: DT120 ODT utilizes Catalent's Zydis® ODT fast-dissolve technology, offering faster absorption and reduced gastrointestinal side effects, aimed at improving patient experience and advancing mental health treatment progress.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research and Funding
- Policy Acceleration for Psychedelic Research: Trump signed an executive order directing federal agencies to expedite psychedelic research and approvals, committing $50 million for related clinical studies, which is expected to significantly shorten treatment drug approval timelines, thereby providing faster treatment options for mental health patients.
- Market Potential Analysis: Koyfin consensus estimates indicate that Compass Pathways (CMPS) has a 12-month average analyst price target of $21.75, implying a 227% upside, while Definium Therapeutics (DFTX) stands at $36.67, suggesting a 62% potential increase, highlighting CMPS's greater valuation upside following the policy shift.
- Clinical Trial Progress: Both Definium's DT120 (LSD-based) and Compass's COMP360 (psilocybin) are advancing through late-stage clinical trials in the U.S. targeting psychiatric conditions such as anxiety and depression, with the potential to offer new treatment options for patients, especially under Trump's supportive policy.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for both DFTX and CMPS is extremely bullish, with DFTX stock surging nearly 300% over the past year and CMPS more than doubling, reflecting strong market interest and confidence in psychedelic drug development.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Superstring Capital Increases Stake in Definium Therapeutics
- New Investment Disclosure: Superstring Capital Management disclosed the acquisition of 425,202 shares of Definium Therapeutics in Q4 2026, totaling $5.69 million, indicating confidence in the company's growth potential and future prospects.
- Portfolio Composition: The DFTX position accounts for 3.05% of Superstring's reportable U.S. equity assets, highlighting a strategic focus on clinical-stage biotech, particularly in the evolving neuroscience therapeutics market.
- Strong Market Performance: Definium Therapeutics' shares surged 170% over the past year, significantly outperforming the S&P 500's 19% gain, reflecting positive market sentiment towards its innovative drug development and investor confidence.
- Robust Financial Position: The company ended the year with over $400 million in cash and investments, sufficient to fund operations into 2028, thereby reducing short-term dilution risk and providing financial stability for upcoming clinical trials, which boosts investor confidence.
See More
Superstring Capital Management Acquires Definium Shares
- Investment Scale: Superstring Capital Management acquired 425,202 shares of Definium Therapeutics in Q4 2026, totaling $5.69 million, reflecting confidence in the company's clinical-stage biopharmaceutical focus.
- Financial Position: Definium Therapeutics ended the year with over $400 million in cash and investments, sufficient to fund operations into 2028, thereby reducing near-term dilution risks and enhancing market competitiveness.
- Clinical Progress: Definium is approaching multiple Phase 3 trial readouts, particularly for depression and anxiety programs, with Emerge topline data expected next quarter in 2026, which could rapidly alter the company's valuation.
- Market Performance: Despite a 30% rise in Definium Therapeutics' stock this year, the Motley Fool analyst team did not include it in their top investment stocks, indicating a cautious market outlook on its future performance.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Definium Supports White House Executive Order on Mental Health
- Policy Support: Definium Therapeutics expresses support for the newly signed White House Executive Order aimed at accelerating research and development of innovative treatments for mental illness, highlighting the administration's recognition of unmet treatment needs in serious mental health conditions.
- Clinical Development Plan: The company is advancing a comprehensive clinical development program for DT120 (lysergide tartrate) targeting millions of patients with generalized anxiety disorder and major depressive disorder, aiming to provide new treatment options that enhance patient quality of life.
- FDA Approval Pathway: Definium emphasizes that the FDA's evidence-based approval process is the most effective route for safely translating new therapies into clinical use, ensuring patients have access to these innovative treatments.
- Technological Advantages: DT120 ODT utilizes Catalent's Zydis® ODT fast-dissolve technology, offering faster absorption and reduced gastrointestinal side effects, aimed at improving patient experience and advancing mental health treatment progress.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research and Funding
- Policy Acceleration for Psychedelic Research: Trump signed an executive order directing federal agencies to expedite psychedelic research and approvals, committing $50 million for related clinical studies, which is expected to significantly shorten treatment drug approval timelines, thereby providing faster treatment options for mental health patients.
- Market Potential Analysis: Koyfin consensus estimates indicate that Compass Pathways (CMPS) has a 12-month average analyst price target of $21.75, implying a 227% upside, while Definium Therapeutics (DFTX) stands at $36.67, suggesting a 62% potential increase, highlighting CMPS's greater valuation upside following the policy shift.
- Clinical Trial Progress: Both Definium's DT120 (LSD-based) and Compass's COMP360 (psilocybin) are advancing through late-stage clinical trials in the U.S. targeting psychiatric conditions such as anxiety and depression, with the potential to offer new treatment options for patients, especially under Trump's supportive policy.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for both DFTX and CMPS is extremely bullish, with DFTX stock surging nearly 300% over the past year and CMPS more than doubling, reflecting strong market interest and confidence in psychedelic drug development.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Superstring Capital Increases Stake in Definium Therapeutics
- New Investment Disclosure: Superstring Capital Management disclosed the acquisition of 425,202 shares of Definium Therapeutics in Q4 2026, totaling $5.69 million, indicating confidence in the company's growth potential and future prospects.
- Portfolio Composition: The DFTX position accounts for 3.05% of Superstring's reportable U.S. equity assets, highlighting a strategic focus on clinical-stage biotech, particularly in the evolving neuroscience therapeutics market.
- Strong Market Performance: Definium Therapeutics' shares surged 170% over the past year, significantly outperforming the S&P 500's 19% gain, reflecting positive market sentiment towards its innovative drug development and investor confidence.
- Robust Financial Position: The company ended the year with over $400 million in cash and investments, sufficient to fund operations into 2028, thereby reducing short-term dilution risk and providing financial stability for upcoming clinical trials, which boosts investor confidence.
See More
Superstring Capital Management Acquires Definium Shares
- Investment Scale: Superstring Capital Management acquired 425,202 shares of Definium Therapeutics in Q4 2026, totaling $5.69 million, reflecting confidence in the company's clinical-stage biopharmaceutical focus.
- Financial Position: Definium Therapeutics ended the year with over $400 million in cash and investments, sufficient to fund operations into 2028, thereby reducing near-term dilution risks and enhancing market competitiveness.
- Clinical Progress: Definium is approaching multiple Phase 3 trial readouts, particularly for depression and anxiety programs, with Emerge topline data expected next quarter in 2026, which could rapidly alter the company's valuation.
- Market Performance: Despite a 30% rise in Definium Therapeutics' stock this year, the Motley Fool analyst team did not include it in their top investment stocks, indicating a cautious market outlook on its future performance.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
